Portal vein thrombosis and liver cirrhosis: Long-term anticoagulation is effective and safe - 25/07/19
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Portal vein thrombosis is a common complication of liver cirrhosis. |
• | Anticoagulation therapy is efficient, but is associated with potentially severe side-effects, especially bleeding episodes. It is therefore still unclear which patients will benefit from anticoagulation, and for what duration. |
• | Anticoagulation allows a recanalization of PVT complicating cirrhosis in the majority of the cases and is associated with non-severe bleeding complications. |
• | Anticoagulation can be maintained for a long duration in order to avoid recurrence. |
Summary |
Background and aims |
Portal vein thrombosis (PVT) is a common complication of liver cirrhosis. Anticoagulation therapy is efficient, but is associated with potentially severe side-effects, especially bleeding episodes. It is therefore still unclear which patients will benefit from anticoagulation, and for what duration. The aim of the present study was to retrospectively analyse our single centre experience on long-term anticoagulation in patients presenting a PVT, complicating cirrhosis.
Methods |
Data of 40 cirrhotic patients with PVT treated by anticoagulation therapy from June 2003 to May 2018 were collected. Regular imaging was performed to monitor the outcome of PVT. The hemorrhagic complications and the recurrence of the PVT after anticoagulation withdrawal were also analyzed.
Results |
The median follow-up under anticoagulation therapy was 33.7 months. Complete (57.5%) or partial (25.0%) recanalization of PVT was observed. Fifteen bleeding episodes (37.5%) occurred in our population, related to portal hypertension in 7 (46.7%). Eleven (73.3%) patients required hospitalization and eight (53.3%) required blood transfusion. No patient died from bleeding complication. Anticoagulation was stopped in 10 patients (25.0%), because of regression of PVT in 5 patients or a haemorrhagic episode in 5 patients. Among those 10 patients, 7 had a recurrence or extension of the initial PVT.
Conclusions |
Our results confirm that anticoagulation allows a recanalization of PVT complicating cirrhosis in the majority of the cases, is associated with non-severe bleeding complications, and can be maintained for a long duration in order to avoid recurrence.
Le texte complet de cet article est disponible en PDF.Keywords : Liver cirrhosis, Portal vein thrombosis, Anticoagulation, Bleeding, Outcome, Recurrence
Plan
Vol 43 - N° 4
P. 395-402 - août 2019 Retour au numéro
Article précédent
- Predictive criteria of response to endoscopic treatment for severe strictures in primary sclerosing cholangitis
- Nora Cazzagon, Olivier Chazouillères, Christophe Corpechot, Sanaâ El Mouhadi, Edouard Chambenois, Benoit Desaint, Ulriikka Chaput, Sara Lemoinne, Lionel Arrivé
- mTOR inhibitors in pediatric liver transplant recipients
- Jérôme Dumortier, Eduardo Couchonnal, Florence Lacaille, Christine Rivet, Dominique Debray, Olivier Boillot, Alain Lachaux, Oanez Ackermann, Emmanuel Gonzales, Barbara E. Wildhaber, Emmanuel Jacquemin, Valérie McLin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?